PROTEOMIC EFFECTS OF THE COAGULATION PROTEINASE THROMBIN ON LX-2 HEPATIC STELLATE CELLS

PROTEOMI^KI UTICAJ KOAGULACIJSKE PROTEINAZE TROMBINA NA LX-2 STELATNE ^ELIJE JETRE

Roland Kaufmann1, Franziska Mußbach1*, Annett Urbanek2, Utz Settmacher1, Ferdinand von Eggeling2

1Department of General, Visceral and Vascular Surgery (*Experimental Transplantation Surgery), Jena University Hospital, Jena, Germany
2Institute of Human Genetics, Core Unit Chip Application, Jena University Hospital, Jena, Germany

Summary
Background: The aim of this study was to characterize the effects of the coagulation proteinase thrombin on proteomic level in human hepatic stellate LX-2 cells.
Methods: Proteomic analyses were performed using surface-enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS). The protein profiles obtained from LX-2 cell lysates using strong anion exchanger Q10 ProteinChip arrays were statistically analyzed.
Results: The peak intensities of 50 protein/peptide clusters were identified as being different between nonstimulated and LX-2 cells treated with thrombin for 6 h and 24 h, respectively. As the most significantly enhanced single signal in LX-2 cells stimulated with thrombin, a protein with a molecular mass of 13.560 kDa has been identified that corresponds exactly to calcium dependent phospholipase 2 (cPLA2). Thrombin-induced increase in the cPLA2 protein expression in LX-2 cells was confirmed by using the Western blotting technique.
Conclusions: Together with the finding that thrombin induced phosphorylating activation of cPLA2 in LX-2 cells, our data point to an important function of the thrombin-mediated modulation of cytosolic phospholipase A2 in hepatic stellate cells.
Keywords: thrombin, hepatic stellate cells, LX-2, proteomic profiling, mass spectrometry

Kratak sadr`aj
Uvod: Cilj ove studije bio je da se odredi uticaj koagulacijske proteinaze trombina na proteomi~ki nivo u huma~nim stelatim LX-2 ^elijama jetre.
Metode: Proteomi~ke analize izvr{ene su pomo}u tehnike SELDI-TOF-MS. Statisti~ki su analizirani proteinski profili dobijeni iz lizata LX-2 ^elija pomo}u jakog anjonskog izmenjiva~a i Q10 ProteinChip arrays.
Rezultati: Identifikovani su pik intenziteti 50 klastera proteina/peptida koji su utvr|eni da se razlikuju izme|u nestimuliranim i LX-2 ^elijama tretiranim trombinom tokom 6, odnosno 24 h. Kao najzna~ajniji unapre|en pojedina~ni signal u LX-2 ^elijama stimulisanim trombinom, identifikovan je protein s molekulskom masom od 13,560 kDa koji ta~no odgovara fosfolipazi 2 zavisno od kalcijuma (cPLA2). Porast proteinske ekspresije cPLA2 izazvan trombinom u LX-2 ^elijama potvr|en je pomo}u tehnike western blotinga.
Zaklju~ak: Pored nalaza da je trombin izazvao fosfolipazijsku aktivaciju cPLA2 u LX-2 ^elijama, na{i podaci ukazuju i na va`nu funkcijsku modulaciju citosolne fosfolipaze A2 u stelatim ^elijama jetre posredstvom trombina.
Klju~ne re~i: trombin, stelatne ^elije jetre, LX-2, proteomi~ko profilisanje, masena spektrometrija

Address for correspondence:
Dr. Roland Kaufmann
Experimental Transplantation Surgery, Department of
General, Visceral and Vascular Surgery, Erlanger Allee 101,
D-07747 Jena, Germany
Phone: +49-9396666/ Fax:+49-9396669
e-mail: roland.kaufmann@med.uni-jena.de
Introduction

Beside its critical role in blood coagulation, the serine proteinase thrombin (EC 3.4.21.5) is known to evoke biological responses from a variety of cells, e.g. platelets, fibroblasts, vascular smooth muscle cells and monocytes (1–3), and may influence a number of cellular responses that play a role in subsequent pro-inflammatory and profibrotic processes in different organs including the liver (4).

Recent data suggest a role for thrombin in the activation of hepatic stellate cells (HSCs) that has been recognized as a central event in the development of liver fibrosis and finally cirrhosis and malignancy. More specifically, thrombin has been shown to stimulate matrix synthesis and the regulation of MCP1-production of cultured hepatic stellate cells (6–8). Hepatic stellate cells also express the protease activated receptors 1 and 4 (8), members of a novel subfamily of G-protein coupled receptors mediating the cellular effects of thrombin in different cell types.

Surface-enhanced laser desorption/ionization mass spectrometry (SELDI-MS) is a proteomic analysis (10) that has been demonstrated to be a very suitable approach to evaluate complex variations on protein level in tissue and cells (11, 12).

In this study, we used SELDI-MS to evaluate the effect of thrombin on protein expression profiles in cells of the human stellate cell line LX-2 that has been characterized comprehensively as a suitable model for investigations on liver fibrosis (13). For that purpose, lysates from nonstimulated LX-2 cells and LX-2 cells stimulated with thrombin (1.0 NIH-Unit/mL) for 6 h and 24 h, respectively, were evaluated using strong anion exchanger Q10 ProteinChip arrays.

Materials and Methods

Reagents

Human alpha-thrombin (3085 NIH-Units/mg protein) was purchased from Haemochrom Diagnostica Supplies (Essen, Germany). All the other reagents were of the highest purity available.

Cell culture

LX-2 cells (gift from Prof. Scott Friedman, Mount Sinai School of Medicine, New York, USA) were routinely cultured in Dulbeccos modified Eagle’s medium (DMEM) supplemented with 2% fetal calf serum at 37 °C in a humidified atmosphere of 5% CO2. The medium was changed every 2–3 days. For subculturing, treatment with trypsin/EDTA was used.

For stimulation experiments, LX-2 cells were cultured in 6-well plates, serum starved for 16 h and subsequently stimulated with thrombin (Haemochrom Diagnostica Supplies; 1.0 NIH-Unit/mL).

ProteinChip array and analysis

Cells were transferred into tubes with lysis buffer (100 mmol/L Na3HPO4, 2 mmol/L MgCl2, 5 mmol/L EDTA, 3 mmol/L β-mercaptopethanol, 0.1% CHAPS, 500 μmol/L leupeptin, 0.1 mmol/L PMSF). After 1h incubation on ice with mixing every 15 minutes, the samples were centrifuged with 14,000 rpm at 4 °C to remove cell debris.

Proteins were analyzed on strong anion exchange arrays (Q10; BioRad) as described elsewhere (14). In brief, array spots were preincubated by a washing/loading buffer containing 100 mmol/L Tris-buffer, pH 8.5 with 0.02% Triton X-100 for Q10 arrays and 100 mmol/L Tris-buffer, pH 4.5 with 0.02% Triton X-100 for CM10 arrays followed by application of 2 μL of sample extract on ProteinChip Arrays, which were incubated at room temperature for 90 min in a humidity chamber. After washing three times with the same buffers and two final washing steps with water, 2 × 0.5 μL sinapinic acid (saturated solution in 0.5% TFA/50% acetonitrile) were applied. Mass analysis was performed in a ProteinChip system (PCS 4000, Ciphergen Biosystems Inc, Fremont, CA) according to an automated data collection protocol. The instrument was externally calibrated with a ProteinChip OQ Kit (Biorad) for improved mass accuracy. Spectra were normalized with total ion current and cluster analyses of the detected signals and the determination of respective P-values were carried out with the CiphergenExpress Program (Version 3.0; Ciphergen Biosystems Inc, Fremont, CA). For P-value calculation, normalized spectra with signals in the range between 2.5 and 200 kDa exhibiting a signal-to-noise ratio (S/N) of at least 10 were selected and analyzed with the Mann–Whitney U test for nonparametric data.

Western blotting analysis

LX-2 cells were collected by centrifugation at 1000 × g for 5 min (4 °C), washed with PBS containing bacitracin (100 μg/mL), PMSF (0.1 mmol/L), pepstatin A (1.0 μg/mL) and leupeptin (2.0 μg/mL), pH 7.4, and centrifuged again. The pellet was treated with lysis buffer (PBS, containing 1% (v/v) Triton X-100, 0.5% (w/v) deoxycholate and 0.1% (w/v) SDS) for 30 min at 4 °C, resuspended and centrifuged at 30000 × g for 15 min (4 °C).

Protein was determined using the DC Protein Assay System from BioRad Laboratories according to the manufacturer’s instructions.
Proteins from cell lysates were separated on a 12% SDS/PAGE and transferred to nitrocellulose membranes (BioRad). After blocking in 1% BSA/1% skimmed milk for 1 h, the nitrocellulose strips were incubated overnight with the respective first antibody. For the estimation of phosphorylating activation of cPLA2 phospho (Ser 505) cPLA2-antibody (Cell Signaling Technology, No. 2831) and for estimation of the cPLA2 protein expression, an antibody to total cPLA2 (Cell Signaling Technology, No. 2832) was used. Strips were washed two times with 0.05% (v/v) Tween 20 washing buffer, incubated for 45 min with the secondary antibody (anti-rabbit IgG conjugated to horseradish peroxidase) and washed again two times as described above. The immunoblots were stripped and reprobed with an antibody to total cPLA2 (cPLA2 activation experiments) or with an antibody to beta-actin (Sigma-Aldrich, No. A 5441; cPLA2 protein expression experiments) to confirm equal protein loading. Secondary antibody (anti-rabbit IgG conjugated to horseradish peroxidase or anti-mouse IgG conjugated to horseradish peroxidase) was detected by using the chemiluminescence (ECL) Western blotting detection system (Amersham) and exposure to Kodak X-Omat films.

Immunoreactive bands for phosphorylated cPLA2, total cPLA2 and beta-actin were quantified using the image processing program Image J 1.43 (National Institutes of Health, Bethesda, Maryland, USA).

Results

Protein lysates from nonstimulated LX-2 cells and LX-2 cells stimulated with thrombin (1.0 NIH-Units/mL) for 6 h and 12 h, respectively, were applied to strong anion exchanger Q10 ProteinChip arrays and analysed individually by SELDI–MS on a PCS 4000 instrument to detect any differentially expressed proteins. In the low range of 2.5–20 kDa, up to 50 peaks were detected. After evaluation with CiphergenExpress Program, a mass with a highly significant P-value was identified. This signal of 13.560 kDa was upregulated in thrombin-stimulated LX-2 cells discriminated significantly between nonstimulated LX-2 cells and cells stimulated with thrombin (1.0 NIH-Units/mL) for both 6 h (P=0.05) and 24 h (P=0.01). The measured intensities for nonstimulated and thrombin-treated LX-2 cells are depicted in Figure 1. By enquiring the ExPasy protein database (http://www.expasy.org) with a specified Mw range of 13560 Da +/- 0.4 % and a pl range from 6 to 10, we found that the size of the protein with the mass of 13.560 kDa matches to the chain 21-138 of calcium-dependent phospholipase A2 (UniProt: PA2G5_ HUMAN; P39877; Mw13591, pI 8.73).

Our data obtained with the use of proteinchip technology singled out a role for cPLA2 in thrombin’s signalling activity in LX-2 hepatic stellate cells. To confirm these data, we investigated the effect of thrombin on cPLA2 protein expression by Western blotting. We found that stimulation of LX-2 cells with thrombin (1.0 NIH-U/mL) resulted in a significant increase of cPLA2 protein expression (Figure 2A). Since thrombin is known to activate cPLA2 in different cell types (15–17), we wished furthermore to evaluate thrombin-mediated activation of the enzyme in LX-2 cells, using a Western blot approach that monitors increases in phospho(P)-cPLA2 following the exposure of cells to thrombin. As demonstrated in Figure 2B, stimulation of LX-2 cells for 20 min caused an approximately 2-fold increase in P-cPLA2 immunoreactivity, relative to the signal observed in nonstimulated LX-2 cells.

Figure 1 Distribution of the intensities of the peak at 13.560 kDa expressed significantly differently in nonstimulated (control) and LX-2 cells stimulated with thrombin (1.0 NIH-Unit/mL) for 6 h (A) and 24 h (B). X-axis indicates the sample groups, Y-axis the intensity (µA).
Liver fibrosis is the major complication of most chronic liver diseases, leading eventually to cirrhosis and finally to carcinoma. It is characterized by a massive deposition of extracellular matrix (ECM) components in the liver parenchyma. Synthesis of ECM components is performed by fibrogenic cells that derive from the activation of quiescent precursors such as hepatic stellate cells. Therefore, these cells play a key role in liver fibrosis and are also discussed as crucial cellular elements for the malignant process in the liver (5). In this study, we demonstrate an effect of the serine proteinase thrombin on the proteomic level in cells from the human hepatic stellate cell line LX-2 using SELDI ProteinChip technology. LX-2 cells have been extensively characterized and retain key features of cytokine signalling, neuronal gene expression, retinoid metabolism, and fibrogenesis, making them highly suitable for culture based studies of human hepatic fibrosis (13).

Proteomic analysis revealed that treatment of LX-2 cells with thrombin upregulated a single protein with a molecular mass corresponding to the chain 21-138 of calcium-dependent phospholipase A2. The effect of thrombin on the PLA2 protein expression was confirmed by Western blotting. Moreover, thrombin could be shown to induce phosphorylating activation of cPLA2 in LX-2 cells. Phospholipase A2 enzymes catalyze the hydrolysis of the sn-2 position of glycerophospholipids to release free arachidonic acid, which in turn is metabolized to prostaglandins by the cyclooxygenase pathway and to leukotrienes by the 5-lipoxygenase pathway (for review see e.g. 18). PLA2 is known to be involved in hepatic stellate cell activation (19) and is critically implicated in thrombin-induced signalling in different cell types including platelets (20, 21) and endothelial cells (22–24). In addition, from recently published data, a role for thrombin in liver fibrosis and hepatocellular carcinoma progression has been suggested (25, 26).

Our study provides evidence for a link between thrombin and PLA2 in hepatic stellate cells. Thrombin’s role in HSC cell activation during liver fibrosis and carcinogenesis has to be explored in further studies, including experiments on primary cultures of hepatic stellate cells and animal models.

Taken together, our data demonstrate that proteomic analysis is a suitable approach to evaluate effects of a single stimulus on protein level in hepatic stellate cells. With our results we support the concept of a function for the coagulation proteinase thrombin in hepatic stellate cell activation, and more generally, for coagulation enzymes in liver fibrosis.

**Conflict of interest statement**

The authors stated that they have no conflicts of interest regarding the publication of this article.
References

1. Glenn K, Carney D, Fenton J, Cunningham D. Thrombin active-site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem 2004; 255: 6609–16.

2. Bar-Shavit R, Mudd M, Wilner G, Mann K, Fenton JWII. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 1985; 220: 728–31.

3. Berndt M, Philpips D. Platelet membrane proteins: composition and receptor function. In: Gordon J, editor. Platelets in biology and pathology. Amsterdam/ North Holland, 1981: 43–7.

4. Duplantier JG, Dubuisson L, Senant N, Freyburger G, Laurendeau I, Herbert JM, et al. A role for thrombin in liver fibrosis. Gut 2004; 53: 1682–7.

5. Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013; 5: 217–30K.

6. Mallat A, Gallois C, Tao J, et al. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem 1998; 273: 27500–5.

7. Gaça MD, Zhou X, Benyon RC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol 2002; 36: 362–9.

8. Fiorucci S, Antonelli E, Distruitti E, Severino B, Fiorentina R, Baldoni M, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004; 39: 365–75.

9. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 2012; 11: 69–86.

10. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004; 23: 34–44.

11. Clarke W, Zhang Z, Chan DW. The application of clinical proteomics to cancer and other diseases. Clin Chem Lab Med 2005; 41: 1562–70.

12. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM. Applications of SELDI-MS technology in oncology. J Cell Mol Med 2008; 12(SA): 1535–47.

13. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142–51.

14. Melle C, Bogumil R, Ernst G, Schimmel B, et al. Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics 2006; 6: 2600–8.

15. Kramer RM, Roberts EF, Manetta JV, Sportman JR, Jakubowski JA. Ca(2+)-sensitive cytosolic phospholipase A2 (cPLA2) in human platelets. J Lipid Mediat 1993; 6: 209–16.

16. Puri RN. Phospholipase A2: its role in ADP- and thrombin-induced platelet activation mechanisms. Int J Biochem Cell Biol 1998; 30: 1107–22.

17. Gluck N, Schwob O, Krinsky M, Edgard S. Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation. Am J Physiol Cell Physiol 2008; 294: C1597–605.

18. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997; 272: 16709–12.

19. Cardoso CC, Pavia ER, Cruz LA, Guma FC, Borovec R, Guaragna RM. Effect of pentoxifylline on arachidonic acid metabolism, neutral lipid synthesis and accumulation during induction of the lipocyte phenotype by retinol in murine hepatic stellate cell. Mol Cell Biochem 2003; 254: 37–46.

20. Akiba S, Sato T, Fujii T. Evidence for an increase in the association of cytosolic phospholipase A2 with the cytoskeleton of stimulated rabbit platelets. J Biochem 1993; 113: 4–6.

21. Akiba S, Kawauchi T, Sato T. Acceleration of Ca2+ ionophore-induced arachidonic acid liberation by thrombin without the proteolytic action toward the receptor in human platelets. Eur J Biochem 1999; 259: 643–50.

22. Garcia JC. Molecular mechanisms of thrombin-induced human and bovine endothelial cell activation. J Lab Clin Med 1992; 120: 515–19.

23. Sato Y, Katoaka H, Asada Y, Marutsuka K, Kamikubo Y, Koono M, Sumiyoshi A. Overexpression of tissue factor pathway inhibitor in aortic smooth muscle cells inhibits cell migration induced by tissue factor/factor VIIa complex. Thromb Res 1999; 94: 401–6.

24. Shah B, Shah G. Antifibrotic effect of heparin on liver fibrosis model in rats. World J Gastrointest Pharmacol Ther 2012; 3: 86–92.

25. Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Homann M, et al. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 2007; 211: 699–707.

Received: July 1, 2013
Accepted: December 19, 2013